Constant Therapeutics today announced that its peptide drug TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7), will be tested in a Phase 2 clinical trial at Columbia University Irving Medical Center in New York, New York.… Read more »
Constant Therapeutics’ TXA127 to be tested in Multiple Clinical Trials for COVID-19 Patients
Constant Therapeutics today announced that its peptide drug TXA127 will be tested in a series of Phase 2 clinical trials in hospitalized COVID-19 patients who are not in the Intensive Care Unit (ICU)…… Read more »
Constant Pharmaceuticals, LLC Announces name change to Constant Therapeutics, LLC
Constant Pharmaceuticals, LLC, a privately held biopharmaceutical company focused on the treatment of stroke recovery and epidermolysis bullosa, today announced that they are changing their name to Constant Therapeutics, LLC.… Read more »
Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)
Constant Pharmaceuticals today announced that it plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, epidermolysis bullosa in collaboration with four EB focused charities – DEBRA (Austria), Cure-EB, the Epidermolysis Bullosa Research Partnership (EBRP), and the Epidermolysis Bullosa Medical Research Foundation (EBMRF).… Read more »
Constant Pharmaceuticals, LLC Announces European Patent Issuance for TXA127 in Treatment of Stroke
Constant Pharmaceuticals today announced that the European Patent Office (EPO) has notified the company that it will grant a patent covering the use of TXA127 in the treatment of stroke. … Read more »
Constant Pharmaceuticals, LLC Announces Japanese Patent Issuance for TXA302 in Treatment of Stroke
Constant Pharmaceuticals today announced that the Japanese Patent Office has issued a patent covering the use of TXA302 in the treatment of stroke. … Read more »